NICE gives thumbs-up to Amgen bone drug

The U.K.'s cost-effectiveness watchdog has approved Amgen's (AMGN) osteoporosis drug Prolia (denosumab) for routine use by the National Health Service in postmenopausal patients who are at increased risk of osteoporotic bone fractures. Report

Suggested Articles

AstraZeneca
Pharma

Has AstraZeneca finally found a place for tremelimumab?

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

by Carly Helfand
Lenvima
Pharma

Merck pads case for liver cancer nod with Keytruda-Lenvima data

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

by Carly Helfand
Ibrance
Pharma

Pfizer's Ibrance fails early breast cancer trial

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

by Carly Helfand